Kim Blackwell is a C-Suite Executive and Board Member specializing in oncology therapeutics development and consulting.

She recently served as Chief Executive Officer at Zentalis Pharmaceuticals (2022-2024) and holds educational credentials from Duke University, including a Bachelor’s degree in Bioethics/Medical Ethics and completion of the Medical Oncology Residency Program at Duke University School of Medicine.

Kim currently serves on multiple boards including Susan G. Komen (since March 2024), Fore Biotherapeutics (since June 2021), Century Therapeutics (since May 2021), and Monte Rosa Therapeutics (since June 2020). Based in Denver, Colorado, she combines extensive oncology clinical expertise with executive leadership experience to guide biotechnology companies developing cancer therapeutics.

Her portfolio of board positions reflects her deep involvement in advancing innovative oncology treatments across diverse therapeutic approaches.